ArticleInternational journal of molecular sciences2026
Comparison of Prime Editing and CRISPR-Cas Mediated HDR in Correcting CFTR-F508del Mutation in Patient iPSC-Derived Airway Basal Cells.
Olga Volodina, Anna Demchenko, Ekaterina Kondrateva, Arina Anuchina, Oxana Ryzhkova, Valeriia Kovalskaia, Vyacheslav Tabakov, Elena Amelina, Alexander Lavrov, Sergey Kutsev and 1 more
Abstract readComparative Study
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Olga VolodinaLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow 115522, Russia.
Anna DemchenkoLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow 115522, Russia.
Ekaterina KondratevaLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow 115522, Russia.ORCID 0000-0003-0770-2569 Arina AnuchinaLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow 115522, Russia.
Oxana RyzhkovaThe Shared Resource Centre "Genome", Research Centre for Medical Genetics, Moscow 115522, Russia.
Valeriia KovalskaiaThe Shared Resource Centre "Genome", Research Centre for Medical Genetics, Moscow 115522, Russia.
Vyacheslav TabakovThe Shared Resource Centre "Biobank", Research Centre for Medical Genetics, Moscow 115522, Russia.
Elena AmelinaLaboratory of Cystic Fibrosis, Research Institute of Pulmonology, Moscow 115682, Russia.ORCID 0000-0002-5356-9415 Alexander LavrovLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow 115522, Russia.ORCID 0000-0003-4962-6947 Sergey KutsevLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow 115522, Russia.
Svetlana SmirnikhinaLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow 115522, Russia.ORCID 0000-0002-1558-3048 Funding
LLC "MK Development" 220724The Ministry of Education and Science of the Russian Federation none
6 · The paper itselfAbstract
Gene editing therapy represents a promising strategy to permanently cure cystic fibrosis (CF). This paper presents the results of correcting the most common CF mutation, F508del, in the
Indexed as
CRISPR-Cas SystemsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorGene EditingInduced Pluripotent Stem CellsMutationRecombinational DNA RepairBenzodioxolesGenetic TherapyHumansQuinolonesBenzodioxolesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorQuinolonesCFTRCRISPR-Cascystic fibrosisF508delgene editinggene therapyprime editing
Identifiers
PMID42883863
PMCPMC13665346
What OpenQuestion holds
Textmetadata
Read underepoch 390